RecruitingNCT05481437

A Survey of Brentuximab Vedotin in Pediatric Participants With Hodgkin Lymphoma

Specified Drug Use Surveillance for ADCETRIS Intravenous Infusion 50 mg -Untreated CD30 Positive Hodgkin Lymphoma (Pediatric)

Sponsor

Takeda

Enrollment

8 participants

Start Date

Aug 1, 2022

Study Type

OBSERVATIONAL

Conditions

Hodgkin Lymphoma

Summary

This study is a survey in Japan of Brentuximab Vedotin used to treat children or teenagers with Hodgkin lymphoma (HL). The study sponsor will not be involved in how the participants are treated but will provide instructions on how the clinics will record what happens during the study. The main aim of the study is to check for side effects related from Brentuximab Vedotin especially myelosupression, peripheral neuropathy, and lung disorder. During the study, pediatric participants with HL will take Brentuximab Vedotin injection and AVD treatment (doxorubicin hydrochloride, vinblastine sulfate, and dacarbazine) according to their clinic's standard practice. The study doctors will check for side effects from Brentuximab Vedotin for 26 weeks.

Eligibility

Max Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is collecting information (a survey/registry) about how children with Hodgkin Lymphoma are being treated with brentuximab vedotin — a targeted antibody-drug combination that delivers chemotherapy directly to cancer cells expressing a protein called CD30. **You may be eligible if...** - You are under 18 years old - You have Hodgkin Lymphoma that tests positive for CD30 (most Hodgkin Lymphoma does) - You have not previously been treated for Hodgkin Lymphoma - You are receiving brentuximab vedotin together with the chemotherapy drugs doxorubicin, vinblastine, and dacarbazine (AVD) **You may NOT be eligible if...** - You have a known medical reason (contraindication) that prevents you from receiving brentuximab vedotin Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGBrentuximab Vedotin

Brentuximab Vedotin injection, 50 mg, once every 2 weeks

Locations(1)

Takeda selected site

Tokyo, Tokyo, Japan

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05481437

Related Trials

Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances

NCT050924511 location

Evaluating the Impact of Social and Genetic Factors on Outcomes in Adolescent and Young Adult Cancer Survivors

NCT06002828428 locations